Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials

Abstract Objective. Treatment with tumour necrosis factor antagonists (anti-TNF) has been recognized as a risk factor for tuberculosis (TB) reactivation. Our aim was to evaluate risk of TB reactivation in rheumatologic and non-rheumatologic diseases treated with the same anti-TNF agents with and without concomitant therapies. Methods. We searched for randomized controlled trials (RCTs) evaluating infliximab, adalimumab, and certolizumab in both rheumatologic and non-rheumatologic diseases until 2012. Results were calculated as pooled rates and/or pooled odd ratios (OR). Results. Overall, 40 RCTs with a total of 14,683 patients (anti-TNF: 10,010; placebo: 4673) were included. TB reactivation was 0.26% (26/10,010) in the anti-TNF group and 0% (0/4673) in the control group, corresponding to an OR of 24.8 (95% CI 2.4–133). TB risk was higher when anti-TNF agents were combined with methotrexate or azathioprine as compared with either controls (24/4241 versus 0/4673; OR 54; 95% CI 5.3–88) or anti-TNF monotherapy (24/4241 versus 2/5769; OR 13.3; 95% CI 3.7–100). When anti-TNF was used as monotherapy, TB risk tended to be higher than placebo (2/5769 versus 0/4673; OR 4; 95% CI 0.2–15.7). Conclusions. TB risk with anti-TNF agents appeared to be increased when these agents were used in combination with methotrexate or azathioprine as compared with monotherapy regimen. TB risk seemed to be higher than placebo, even when monotherapy is prescribed.

[1]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[2]  P. Deepak,et al.  Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. , 2013, Journal of gastrointestinal and liver diseases : JGLD.

[3]  S. Vermeire,et al.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. , 2012, Journal of Crohn's & colitis.

[4]  W. Sandborn,et al.  Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry , 2012, The American Journal of Gastroenterology.

[5]  S. Schreiber.  Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.

[6]  A. Troxel,et al.  The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. , 2011, Journal of the American Academy of Dermatology.

[7]  K. Papp,et al.  Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. , 2011, Archives of dermatology.

[8]  C. V. van Gils,et al.  Risk factors for idiopathic orbital inflammation: a case–control study , 2010, British Journal of Ophthalmology.

[9]  H. Nakagawa,et al.  Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. , 2010, Journal of dermatological science.

[10]  R. Diel,et al.  The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement , 2010, European Respiratory Journal.

[11]  W. Maksymowych,et al.  A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis , 2010, The Journal of Rheumatology.

[12]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[13]  H. Nakagawa,et al.  Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study , 2010, The Journal of dermatology.

[14]  P. Machado,et al.  Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review , 2010, Clinical Rheumatology.

[15]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[16]  S. Hanauer,et al.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. , 2009, Gastroenterology.

[17]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.

[18]  D Emilie,et al.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. , 2009, Arthritis and rheumatism.

[19]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.

[20]  C. Antoni,et al.  Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. , 2009, The Journal of clinical investigation.

[21]  W. Bishai,et al.  Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry , 2009, Annals of the rheumatic diseases.

[22]  T. Hsieh,et al.  Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.

[23]  N. Goel,et al.  Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study , 2008, Annals of the rheumatic diseases.

[24]  D. M. van der Heijde,et al.  Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial , 2008, Annals of the rheumatic diseases.

[25]  V. Strand,et al.  Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Arthritis and rheumatism.

[26]  T. Einarson,et al.  The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.

[27]  Michael W Kattan,et al.  Meta-analysis: Its strengths and limitations. , 2008, Cleveland Clinic journal of medicine.

[28]  N. Miyasaka.  Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study , 2008, Modern rheumatology.

[29]  Hyon K. Choi,et al.  The risk of hospitalized infection in patients with rheumatoid arthritis. , 2008, The Journal of rheumatology.

[30]  D. Moher,et al.  Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. , 2008, Annals of internal medicine.

[31]  P. Rahman,et al.  Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. , 2007, Arthritis and rheumatism.

[32]  M. Dougados,et al.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2007, Annals of the rheumatic diseases.

[33]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[34]  J. Flynn,et al.  Tumor necrosis factor and tuberculosis. , 2007, The journal of investigative dermatology. Symposium proceedings.

[35]  M. Genovese,et al.  Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. , 2007, Journal of Rheumatology.

[36]  P. Rutgeerts,et al.  Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2007, Gut.

[37]  L. Jacobsson,et al.  Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists , 2007, Annals of the rheumatic diseases.

[38]  B. Miller,et al.  Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. , 2006, Journal of the American Academy of Dermatology.

[39]  M. Dougados,et al.  Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. , 2006, Arthritis and rheumatism.

[40]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[41]  J. Mary,et al.  Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.

[42]  Mahboob Rahman,et al.  The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. , 2006, Arthritis and rheumatism.

[43]  Mahboob Rahman,et al.  Glucocorticoid use, other associated factors, and the risk of tuberculosis. , 2006, Arthritis and rheumatism.

[44]  Frederick Wolfe,et al.  Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. , 2006, Arthritis and rheumatism.

[45]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[46]  D. Gladman,et al.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[47]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[48]  T. British,et al.  BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment , 2005, Thorax.

[49]  D. Gladman,et al.  Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). , 2005, Arthritis and rheumatism.

[50]  B. Dijkmans,et al.  Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). , 2005, Arthritis and rheumatism.

[51]  A. Kavanaugh,et al.  Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial , 2005, Annals of the rheumatic diseases.

[52]  A. Innes,et al.  Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study , 2004, Alimentary pharmacology & therapeutics.

[53]  D. M. van der Heijde,et al.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[54]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[55]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[56]  M. Dougados,et al.  Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.

[57]  V. Strand,et al.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.

[58]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[59]  L. Carmona,et al.  Increased risk of tuberculosis in patients with rheumatoid arthritis. , 2003, The Journal of rheumatology.

[60]  S. Gabriel,et al.  Predictors of infection in rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[61]  S. Gabriel,et al.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.

[62]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.

[63]  M. Röllinghoff,et al.  Induction of TNF in Human Alveolar Macrophages As a Potential Evasion Mechanism of Virulent Mycobacterium tuberculosis1 , 2002, The Journal of Immunology.

[64]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[65]  JoAnne L. Flynn,et al.  Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting Pathology , 2001, Infection and Immunity.

[66]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[67]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[68]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[69]  C. Lowenstein,et al.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. , 1995, Immunity.

[70]  D. Heijde,et al.  Clinical and epidemiological research , 2011 .

[71]  V. Annese,et al.  The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[72]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions : Explanation and Elaboration , 2009 .

[73]  B. Strober,et al.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. , 2008, Journal of the American Academy of Dermatology.

[74]  B. Thiers.  Safety and Efficacy of Adalimumab in Treatment of Patients with Psoriatic Arthritis Who Had Failed Disease Modifying Antirheumatic Drug Therapy , 2008 .

[75]  A. Gottlieb,et al.  A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. , 2007, Journal of the American Academy of Dermatology.

[76]  H. Hashimoto,et al.  A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. , 2006, The Journal of rheumatology.

[77]  P. Rutgeerts,et al.  Randomized , Placebo-Controlled Trial of Certolizumab Pegol CDP 870 ) for Treatment of Crohn ’ s Disease , 2005 .

[78]  BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. , 2005, Thorax.

[79]  Peter Ormerod,et al.  BTS recommendations for assessing risk, and for managing M.tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment British Thoracic Society Standards of Care Committee , 2005 .

[80]  A. Zinsmeister,et al.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.

[81]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[82]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[83]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[84]  Adverse effects of biologics: a network meta‐analysis and Cochrane overview , 2022 .